business

Piper Sandler Maintains Neutral Rating on Marsh & McLennan (MRSH)

Yahoo Finance · May 31, 2026, 9:43 AM · Also reported by 4 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Piper Sandler reiterates Tenax Therapeutics stock rating ahead of trial Investing.com Cantor Fitzgerald reiterates Neutral rating on Pfizer stock Investing.com H.C. Wainwright downgrades Crescent Biopharma stock rating to neutral Investing.com UBS assumes Veritone stock coverage with neutral rating, $2.50 target

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Piper Sandler Maintains Neutral Rating on Marsh & McLennan (MRSH)

Also covered by

More in business